Products

Folio

Easy websites that generate leads for freelancers

folio.cx Marketing / Website & Landing Page Builders

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$5/mo
Lower than 88% of peersNiche median $14.79/mo
Creators
Rubayet
No social account linked
Launched
10mo ago
2026-01-20 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
X accounts@folio
  • Launched on Product HuntLaunch

    Look hireable within minutes

    Jan 20 · 10mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

No traffic channel or country breakdown data for this website yet.

Search

Domain authority —Domain registered 2026-01-17

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Starter
$5/mo
Founders Lifetime
$49/once
Lifetime access to all features

Trial: None · 2 paid tiers ($5–$49) · Observed 2026-11-06 · Source page

Entry price $5/mo, Lower than 88% of peers; “Website & Landing Page Builders” median is $14.79/mo.View pricing benchmark

Website snapshots

Indexed 2026-01-20

Key pages

Desktop & mobile archive
Home
www.folio.cx/ Snapshot 2026-11-07

Questions & evidence

How much does Folio cost?
Starter: $5/mo; Founders Lifetime: $49/once. Observed 2026-11-06. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does Folio get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Folio and what platforms does it support?
Folio is catalogued under Website & Landing Page Builders: Easy websites that generate leads for freelancers. Supported platforms: Web.

Related products in this category

Marketing / Website & Landing Page Builders

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.